Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
Sponsor: The Cleveland Clinic
Terminated
Lack of enrollment
Other terminated trials from The Cleveland Clinic
Other Peripheral Arterial Disease trials with similar outcome
This PHASE2/PHASE3 trial investigates Peripheral Arterial Disease and is currently terminated or withdrawn. The Cleveland Clinic leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
Status: Recruiting → Terminated
▶ Show 6 earlier versions
-
Dec 2019 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2019 — Dec 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .